Literature DB >> 16482387

Molecular analysis and susceptibility profiling of Candida albicans isolates from immunocompromised patients in South India.

C P Girish Kumar1, Ahmed Medhat Hanafy, Masakazu Katsu, Yuzuru Mikami, Thangam Menon.   

Abstract

The genetic diversity and in vitro antifungal susceptibility profiles of 55 Candida albicans from immunocompromised patients were studied. PCR based analysis of the transposable intron in the 25S rDNA revealed 39 genotype A, 4 genotype B and 12 genotype C isolates. Serotype analysis categorized 52 isolates as serotype A and 3 as serotype B. All strains were susceptible to micafungin, 5-flucytosine and miconazole, whereas resistance against amphotericin B (3.6%), fluconazole (3.6%), itraconazole (7.3%) and voriconazole (5.5%) was observed. No association was seen between antifungal resistance and genotype/serotype status.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16482387     DOI: 10.1007/s11046-005-9210-6

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  32 in total

1.  Molecular epidemiology of the global and temporal diversity of Candida albicans.

Authors:  M J McCullough; K V Clemons; D A Stevens
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

Review 2.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

3.  Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.

Authors:  A Espinel-Ingroff; F Barchiesi; M Cuenca-Estrella; A Fothergill; M A Pfaller; M Rinaldi; J L Rodriguez-Tudela; P E Verweij
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

4.  Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis.

Authors:  F Barchiesi; R J Hollis; M Del Poeta; D A McGough; G Scalise; M G Rinaldi; M A Pfaller
Journal:  Clin Infect Dis       Date:  1995-09       Impact factor: 9.079

5.  Intergenic transcribed spacer PCR ribotyping for differentiation of Saccharomyces species and interspecific hybrids.

Authors:  M J McCullough; K V Clemons; J H McCusker; D A Stevens
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

6.  Genotype distribution of Candida albicans isolates by 25S intron analysis with regard to invasiveness.

Authors:  Z C Karahan; H Güriz; H Ağirbaşli; N Balaban; J S Göçmen; D Aysev; N Akar
Journal:  Mycoses       Date:  2004-12       Impact factor: 4.377

7.  Oral Candida albicans isolates from nonhospitalized normal carriers, immunocompetent hospitalized patients, and immunocompromised patients with or without acquired immunodeficiency syndrome.

Authors:  D L Brawner; J E Cutler
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

8.  Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea.

Authors:  M J McCullough; K V Clemons; D A Stevens
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

9.  Candida tropicalis: a major pathogen in immunocompromised patients.

Authors:  J R Wingard; W G Merz; R Saral
Journal:  Ann Intern Med       Date:  1979-10       Impact factor: 25.391

Review 10.  Importance of Candida species other than C. albicans as pathogens in oncology patients.

Authors:  J R Wingard
Journal:  Clin Infect Dis       Date:  1995-01       Impact factor: 9.079

View more
  1 in total

1.  Molecular analysis of Candida albicans isolates from clinical specimens.

Authors:  Melahat Gurbuz; Ilknur Kaleli
Journal:  Mycopathologia       Date:  2009-12-10       Impact factor: 2.574

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.